(OPRX) OPTIMIZERx - Overview
Stock: Platform, Targeting, Messaging, Alerts,
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 76.9% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.10 |
| Alpha | 72.16 |
| Character TTM | |
|---|---|
| Beta | 1.369 |
| Beta Downside | 0.548 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.21% |
| CAGR/Max DD | -0.18 |
Description: OPRX OPTIMIZERx December 31, 2025
OptimizeRx Corp. (NASDAQ:OPRX) is a U.S.-based digital-health technology firm that delivers a suite of data-driven marketing solutions to pharmaceutical manufacturers and healthcare providers. Its core offering, the Dynamic Audience Activation Platform, uses machine-learning-based predictive analytics to build “dynamic audiences” for targeted outreach. Complementary products include Micro-Neighborhood Targeting (privacy-first audience creation), Profiler (consumer insights), a range of banner and therapeutic-support messages, and a full-stack media execution engine that spans programmatic display, connected TV, social, addressable TV, digital out-of-home, audio, and direct-mail channels. Additional services such as pharmacy-stock alerts and embedded financial messaging (e.g., copay-assist visibility within EHR/ePrescribing systems) aim to close the loop between prescriber intent and patient acquisition.
According to the company’s most recent quarterly filing (Q3 2024), OptimizeRx reported $45 million in revenue-a year-over-year increase of roughly 18%-with an adjusted EBITDA margin of 12% and a cash runway extending through the next 12 months. The digital-health advertising market is projected to grow at a 12% CAGR through 2029, driven by pharmaceutical firms shifting spend from traditional to omnichannel digital tactics and by regulatory pressure for transparent patient-support messaging. A key sector catalyst is the rising prevalence of high-cost specialty drugs, which fuels demand for targeted copay-assist and adherence programs-services that OptimizeRx embeds directly into prescriber workflows.
For a deeper quantitative assessment, consider reviewing ValueRay’s proprietary analytics on OPRX’s market positioning.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 34.0k TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 7.52 > 1.0 |
| NWC/Revenue: 34.57% < 20% (prev 36.75%; Δ -2.18% < -1%) |
| CFO/TA 0.07 > 3% & CFO 11.8m > Net Income 34.0k |
| Net Debt (9.09m) to EBITDA (11.5m): 0.79 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.0m) vs 12m ago 3.81% < -2% |
| Gross Margin: 65.31% > 18% (prev 0.63%; Δ 6468 % > 0.5%) |
| Asset Turnover: 65.28% > 50% (prev 53.38%; Δ 11.90% > 0%) |
| Interest Coverage Ratio: 1.30 > 6 (EBITDA TTM 11.5m / Interest Expense TTM 5.62m) |
Altman Z'' -1.70
| A: 0.22 (Total Current Assets 56.3m - Total Current Liabilities 18.5m) / Total Assets 170.3m |
| B: -0.49 (Retained Earnings -84.3m / Total Assets 170.3m) |
| C: 0.04 (EBIT TTM 7.30m / Avg Total Assets 167.8m) |
| D: -1.75 (Book Value of Equity -84.2m / Total Liabilities 48.1m) |
| Altman-Z'' Score: -1.70 = D |
Beneish M -3.01
| DSRI: 0.98 (Receivables 32.2m/26.4m, Revenue 109.5m/88.2m) |
| GMI: 0.96 (GM 65.31% / 62.60%) |
| AQI: 0.93 (AQ_t 0.67 / AQ_t-1 0.71) |
| SGI: 1.24 (Revenue 109.5m / 88.2m) |
| TATA: -0.07 (NI 34.0k - CFO 11.8m) / TA 170.3m) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of OPRX shares?
Over the past week, the price has changed by +1.21%, over one month by -18.24%, over three months by -42.50% and over the past year by +97.64%.
Is OPRX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OPRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.3 | 123.4% |
| Analysts Target Price | 24.3 | 123.4% |
| ValueRay Target Price | 11.2 | 3% |
OPRX Fundamental Data Overview February 03, 2026
P/E Forward = 12.0192
P/S = 1.8316
P/B = 1.6497
P/EG = 1.6078
Revenue TTM = 109.5m USD
EBIT TTM = 7.30m USD
EBITDA TTM = 11.5m USD
Long Term Debt = 24.8m USD (from longTermDebt, last quarter)
Short Term Debt = 3.51m USD (from shortTermDebt, last quarter)
Debt = 28.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.09m USD (from netDebt column, last quarter)
Enterprise Value = 209.7m USD (200.6m + Debt 28.6m - CCE 19.5m)
Interest Coverage Ratio = 1.30 (Ebit TTM 7.30m / Interest Expense TTM 5.62m)
EV/FCF = 17.98x (Enterprise Value 209.7m / FCF TTM 11.7m)
FCF Yield = 5.56% (FCF TTM 11.7m / Enterprise Value 209.7m)
FCF Margin = 10.65% (FCF TTM 11.7m / Revenue TTM 109.5m)
Net Margin = 0.03% (Net Income TTM 34.0k / Revenue TTM 109.5m)
Gross Margin = 65.31% ((Revenue TTM 109.5m - Cost of Revenue TTM 38.0m) / Revenue TTM)
Gross Margin QoQ = 67.20% (prev 63.83%)
Tobins Q-Ratio = 1.23 (Enterprise Value 209.7m / Total Assets 170.3m)
Interest Expense / Debt = 4.03% (Interest Expense 1.15m / Debt 28.6m)
Taxrate = 25.74% (270.0k / 1.05m)
NOPAT = 5.42m (EBIT 7.30m * (1 - 25.74%))
Current Ratio = 3.05 (Total Current Assets 56.3m / Total Current Liabilities 18.5m)
Debt / Equity = 0.23 (Debt 28.6m / totalStockholderEquity, last quarter 122.3m)
Debt / EBITDA = 0.79 (Net Debt 9.09m / EBITDA 11.5m)
Debt / FCF = 0.78 (Net Debt 9.09m / FCF TTM 11.7m)
Total Stockholder Equity = 118.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.02% (Net Income 34.0k / Total Assets 170.3m)
RoE = 0.03% (Net Income TTM 34.0k / Total Stockholder Equity 118.7m)
RoCE = 5.09% (EBIT 7.30m / Capital Employed (Equity 118.7m + L.T.Debt 24.8m))
RoIC = 3.64% (NOPAT 5.42m / Invested Capital 149.2m)
WACC = 9.97% (E(200.6m)/V(229.2m) * Re(10.96%) + D(28.6m)/V(229.2m) * Rd(4.03%) * (1-Tc(0.26)))
Discount Rate = 10.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.35%
[DCF Debug] Terminal Value 61.90% ; FCFF base≈11.7m ; Y1≈7.65m ; Y5≈3.49m
Fair Price DCF = 2.25 (EV 51.1m - Net Debt 9.09m = Equity 42.0m / Shares 18.6m; r=9.97% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 20.99 | EPS CAGR: 2.38% | SUE: -2.27 | # QB: 0
Revenue Correlation: 70.37 | Revenue CAGR: 6.88% | SUE: 0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.04 | Chg30d=+0.015 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=0.86 | Chg30d=+0.086 | Revisions Net=+1 | Growth EPS=+15.7% | Growth Revenue=+12.5%